PPARδ agonists and metabolic diseases

Current Atherosclerosis Reports

Volumn 9, Issue 1, 2007, Pages 72-77

  Kang, Kihwa ^b   Hatano, Ben ^b   Lee, Chih Hao ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYACYL COENZYME A DEHYDROGENASE; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; CITRATE SYNTHASE; FATTY ACID; FATTY ACID BINDING PROTEIN; GLUCOSE; GW 0742; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 2;

ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TARGETING; DYSLIPIDEMIA; ENERGY METABOLISM; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE DISTRIBUTION; TRANSGENIC MOUSE; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; METABOLIC DISEASES; PPAR DELTA;

EID: 33846164791     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02693931     Document Type: Review

References (34)

1. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
2. Hotamisligil GS: Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. Diabetes 2005, 54(Suppl 2):S73-78.
3. Mangelsdorf DJ, Thummel C, Beato M, et al.: The nuclear receptor superfamily: the second decade. Cell 1995, 83:835-839.
4. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ: Nuclear receptors and lipid physiology: opening the X-files. Science 2001, 294:1866-1870.
5. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999, 20:649-688.
6. Lee CH, Olson P, Evans RM: Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003, 144:2201-2207.
7. Kersten S, Seydoux J, Peters JM, et al.: Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 1999, 103:1489-1498.
8. Leone TC, Weinheimer CJ, Kelly DP: A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci U S A 1999, 96:7473-7478.
9. Barak Y, Nelson MC, Ong ES, et al.: PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999, 4:585-595.
10. Kubota N, Terauchi Y, Miki H, et al.: PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 1999, 4:597-609.
11. Rosen ED, Sarraf P, Troy AE, et al.: PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999, 4:611-617.
12. Kliewer SA, Sundseth SS, Jones SA, et al.: Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A 1997, 94:4318-4323.
13. Krey G, Braissant O, L'Horset F, et al.: Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator- dependent receptor ligand assay. Mol Endocrinol 1997, 11:779-791.
14. Lehmann JM, Moore LB, Smith-Oliver TA, et al.: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995, 270:12953-12956.
15. Barak Y, Liao D, He W, et al.: Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci U S A 2002, 99:303-308.
16. Peters JM, Lee SS, Li W, et al.: Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta (delta). Mol Cell Biol 2000, 20:5119-5128.
17. Akiyama TE, Lambert G, Nicol CJ, et al.: Peroxisome proliferator-activated receptor beta/delta regulates very low density lipoprotein production and catabolism in mice on a western diet. J Bio Chem 2004, 279:20874-20881.
18. Lee CH, Olson P, Hevener A, et al.: PPAR delta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci U S A 2006, 103:3444-3449.
19. Wang YX, Lee CH, Tiep S, et al.: Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 2003, 113:159-170.
20. Luquet S, Lopez-Soriano J, Holst D, et al.: Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB J 2003, 17:2299-2301.
21. Wang YX, Zhang CL, Yu RT, et al.: Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol 2004, 2:e294.
22. Cheng L, Ding G, Qin Q, et al.: Cardiomyocyte-restricted peroxisome proliferator-activated receptor-defta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 2004, 10:1245-1250.
23. Planavila A, Rodriguez-Calvo R, Jove M, et al.: Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res 2005, 65:832-841.
24. Sznaidman ML, Haffner CD, Maloney PR, et al.: Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta) - synthesis and biological activity. Bioorg Med Chem Lett 2003, 13:1517-1521.
25. Pelton P: GW-501516 GlaxoSmithKline/Ligand. Curr Opin Investig Drugs 2006, 7:360-370.
26. Oliver WR Jr, Shenk JL, Snaith MR, et al.: A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A 2001, 98:5306-5311.
27. Wallace JM, Schwarz M, Coward P, et al.: Effects of peroxisome proliferator-activated receptor alpha/delta agonists on HDL-cholesterol in vervet monkeys. J Lipid Res 2005, 46:1009-1016.
28. Lee CH, Chawla A, Urbiztondo N, et al.: Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 2003, 302:453-457.
29. Graham TL, Mookherjee C, Suckling KE, et al.: The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice. Atherosclerosis 2005, 18:29-37.
30. Li AC, Binder CJ, Gutierrez A, et al.: Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest 2004, 114:1564-1576.
31. Tanaka T, Yamamoto J, Iwasaki S, et al.: Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci U S A 2003, 100:15924-15929.
32. Leibowitz MD, Fievet C, Hennuyer N, et al.: Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett 2000, 473:333-336.
33. Shin HD, Park BL, Kim LH, et al.: Genetic polymorphisms in peroxisome proliferator-activated receptor delta associated with obesity. Diabetes 2004, 53:847-851.
34. Skogsberg J, McMahon AD, Karpe F, et al.: Peroxisome proliferator activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men. J Intern Med 2003, 254:597-604.